Replies to post #308180 on Innovation Pharmaceuticals Inc (IPIX)

[58nout]

Although the claim of defeating antibiotic resistance may well be true, it's never been proven.
With Merck's folly of acquiring Cubist at a cost of over 9 billion dollars, it's no wonder that they, nor seemingly any other big pharma, is willing to invest in another unproven antibiotic platform, regardless of how promising it might be.

[ROMAD Diver]

The anti-resistance of B is as important as it possibly being anti-viral, -bacterial, and -fungal. If this holds true, then getting a dose of B for COVID-19 will then reduce the occurrence of a lot of other ailments. The price per dose would go up exponentially.

[Lemoncat]

Weren't you under the impression that B-ABSSSI's ability to overcome the antibiotic resistance issue was its primary source of differentiation?

At equal cost? Yes.

Against a much cheaper generic that still works? Apparently not or we would have done a deal.

unmet need issue that resulted from high competition

I don't think there is a large unmet need for ABSSSI at this time. Big pharma and insurance companies are doing the math and taking the patient out of the equation. The existing batch of generics seem to be doing pretty well. Maybe in 10 years that will change but for the useful life of B-ABSSSI it seems it would be playing backup QB.

Go IPIX!